Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Discovering potential serological biomarker for chronic Hepatitis B Virus-related hepatocellular carcinoma in Chinese population by MAL-associated serum glycoproteomics analysis.

Liu T, Liu D, Liu R, Jiang H, Yan G, Li W, Sun L, Zhang S, Liu Y, Guo K.

Sci Rep. 2017 Jan 12;7:38918. doi: 10.1038/srep38918.

2.

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.

Hsu JL, Hung MC.

Cancer Metastasis Rev. 2016 Dec;35(4):575-588. doi: 10.1007/s10555-016-9649-6.

PMID:
27913999
3.

Adaptive Stress Responses During Tumor Metastasis and Dormancy.

Senft D, Ronai ZE.

Trends Cancer. 2016 Aug;2(8):429-442.

PMID:
27868104
4.

Docosahexaenoic Acid Inhibits Tumor Promoter-Induced Urokinase-Type Plasminogen Activator Receptor by Suppressing PKCδ- and MAPKs-Mediated Pathways in ECV304 Human Endothelial Cells.

Lian S, Xia Y, Nguyen TT, Ung TT, Yoon HJ, Kim NH, Kim KK, Jung YD.

PLoS One. 2016 Sep 21;11(9):e0163395. doi: 10.1371/journal.pone.0163395. eCollection 2016.

5.

Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.

Wang S, Jiang L, Han Y, Chew SH, Ohara Y, Akatsuka S, Weng L, Kawaguchi K, Fukui T, Sekido Y, Yokoi K, Toyokuni S.

Oncotarget. 2016 Oct 25;7(43):69565-69578. doi: 10.18632/oncotarget.11829.

6.

Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.

Huber MC, Falkenberg N, Hauck SM, Priller M, Braselmann H, Feuchtinger A, Walch A, Schmitt M, Aubele M.

Oncotarget. 2016 Jul 12;7(28):44062-44075. doi: 10.18632/oncotarget.9853.

7.

uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.

Tarighi P, Montazeri H, Khorramizadeh MR, Sobhani AM, Ostad SN, Ghahremani MH.

Res Pharm Sci. 2015 May-Jun;10(3):200-5.

8.

Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.

Kim KK, Han A, Yano N, Ribeiro JR, Lokich E, Singh RK, Moore RG.

Sci Rep. 2015 Nov 16;5:15911. doi: 10.1038/srep15911.

9.

Integrin α5 Suppresses the Phosphorylation of Epidermal Growth Factor Receptor and Its Cellular Signaling of Cell Proliferation via N-Glycosylation.

Hang Q, Isaji T, Hou S, Im S, Fukuda T, Gu J.

J Biol Chem. 2015 Dec 4;290(49):29345-60. doi: 10.1074/jbc.M115.682229. Epub 2015 Oct 19.

10.

Urokinase receptor and resistance to targeted anticancer agents.

Gonias SL, Hu J.

Front Pharmacol. 2015 Jul 27;6:154. doi: 10.3389/fphar.2015.00154. eCollection 2015. Review.

11.

EGFR Amplification and Glioblastoma Stem-Like Cells.

Liffers K, Lamszus K, Schulte A.

Stem Cells Int. 2015;2015:427518. doi: 10.1155/2015/427518. Epub 2015 Jun 2. Review.

12.
13.

Human sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion.

Mekkawy AH, Morris DL.

ISRN Biochem. 2013 Sep 12;2013:598251. doi: 10.1155/2013/598251. eCollection 2013.

14.

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.

Indira Chandran V, Eppenberger-Castori S, Venkatesh T, Vine KL, Ranson M.

Oncoscience. 2015 Mar 23;2(3):207-24. eCollection 2015. Review.

15.

Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Gilder AS, Jones KA, Hu J, Wang L, Chen CC, Carter BS, Gonias SL.

J Biol Chem. 2015 Jun 12;290(24):14798-809. doi: 10.1074/jbc.M115.637488. Epub 2015 Apr 2.

16.

A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Liu D, Zhou D, Wang B, Knabe WE, Meroueh SO.

ACS Chem Biol. 2015 Jun 19;10(6):1521-34. doi: 10.1021/cb500832q. Epub 2015 Mar 31.

17.

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes.

Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, Ekpin E, George A, Zheng Y, Lam HM, Morrissey C, Chung CY, Farias EF, Bernstein E, Aguirre-Ghiso JA.

Nat Commun. 2015 Jan 30;6:6170. doi: 10.1038/ncomms7170.

18.

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.

Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL.

Oncogene. 2015 Jul 30;34(31):4078-88. doi: 10.1038/onc.2014.336. Epub 2014 Oct 27.

19.

Decreased Mitogen Inducible Gene 6 (MIG-6) Associated with Symptom Severity in Children with Autism.

Russo A.

Biomark Insights. 2014 Oct 6;9:85-9. doi: 10.4137/BMI.S15218. eCollection 2014.

20.

Membrane tension drives ligand-independent integrin signaling.

Böttcher RT, Fässler R.

EMBO J. 2014 Nov 3;33(21):2439-41. doi: 10.15252/embj.201489886. Epub 2014 Sep 17. No abstract available.

Supplemental Content

Support Center